Photo Release: Fujitsu works with the Thai Red Cross Society to contribute to society through the annual 20th FTH Voluntary Blood Donation Day

Food and Healthcare Press Releases Friday January 12, 2018 16:03
Bangkok--12 Jan--PR One Network

Ms. Krittinee Sivakul, Head of HR & Administration Group, Fujitsu (Thailand) Co., Ltd. (FTH) led a group comprising company management and staff at a special executives and 187 employees of the company recently donated blood to the Thai Red Cross Society at "The 20th FTH Voluntary Blood Donation Day 2017". Since the company's first voluntary blood donation drive, over 3,026 Fujitsu staff in Thailand have given precious plasma to help save the lives of patients at hospitals across the country. The company plans for a similar CSR activity in June 2018.


Latest Press Release

ESMO Emphasises Importance of Cancer on Global Health Agenda at WHA

At the World Health Assembly in Geneva, ESMO delivered two statements positioning cancer as a priority on the WHO global agenda. (Photo: https://mma.prnewswire.com/media/696385/WHA_Global_Health_Agenda.jpg ) ESMO advocated the strengthening of health...

Real-World Evidence Shows Clinically Meaningful Weight Loss in People Receiving Saxenda(R)

People treated with Saxenda(R) (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise. The data were presented this week at both the 25th European...

Venus Medtech#s strategic investment in Keystone Heart deepens the technical layout of cerebral embolic protection market

China Venus Medtech (Hangzhou) Inc. announced a partnership agreement for strategic investment and authorization with Keystone Heart. This agreement will grant Venus Medtech the right to exclusively develop, manufacture and sell the 3rd generation...

WCG (WIRB-Copernicus Group) Clinical Services Division Opens Office in Japan

WCG(TM) (WIRB-Copernicus Group(R)) Clinical Services Division, the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the opening of the company's new office in Tokyo, Japan....

Head-to-Head Trial Shows Refixia(R) Achieves Greater Total Factor IX Exposure in People With Haemophilia B Than Recombinant Factor IX-Fc Fusion Protein

Adults with haemophilia B who received a single dose Refixia(R) (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein). The head-to-head paradigm7 trial also observed...

Related Topics